Presentation is loading. Please wait.

Presentation is loading. Please wait.

Biophan Technologies, Inc. Company Overview Michael Weiner, CEO Pharma Finance 2005 Conference June 23, 2005.

Similar presentations

Presentation on theme: "Biophan Technologies, Inc. Company Overview Michael Weiner, CEO Pharma Finance 2005 Conference June 23, 2005."— Presentation transcript:

1 Biophan Technologies, Inc. Company Overview Michael Weiner, CEO Pharma Finance 2005 Conference June 23, 2005

2 Cautionary Statement Certain statements included in this presentation may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this presentation should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this presentation, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

3 Biophan’s Mission Enable over $12 billion worth of medical devices shipping annually safe for use with MRI, and imageable. Many are not: –Guidewires, catheters, endoscopes, biopsy needles –Pacemakers, defibrillators, neurostimulators, drug pumps (safety issues, also imaging issues), pain control devices –Stents, embolism clips, aneurysm clips, artificial hips, knees, most other orthopedics Bring other innovations for competitive advantage to biomedical device and pharmaceutical companies.


5 Summary Financial Information Share Price (06.14.05): $2.72 52-Week High: $3.50 52 Week Low: $0.30 Shares Outstanding: 74 million Float: 65 million Market Cap: $203 million Average Daily Volume: 1,026,650

6 Biophan’s Solutions MRI Safety: (many products contraindicated) –RF filter from Johns Hopkins (heating) –Biophan multi-filar wire solution (heating) –“Anti-Antenna” lead design (induced voltages) Image Compatibility Nanomagnetic particle thin film coatings (Nanoset, LLC and Alfred University) –Minimize image artifacts –Makes catheters, guidewires, stents, and devices visible under MRI

7 Management Stu MacDonald, VP R&D at J&J division, with a 400 person organization Jeff Helfer, VP Engineering – formerly Dir. Of Engineering at the same J&J division John Lanzafame, President, Nanolution Division – former President STS Biopolymers, acquired by Angiotech (ANPI) Robert Wood, VP Finance, Treasured and CFO, CPA in public and private firms And now Dr. Michael Friebe, and Dr. Andreas Melzer, two well known leaders in MRI technologies

8 Biophan-Europe Acquired February, 2005, AMRIS (now Biophan Europe) adds enormous additional capability to Biophan 2 Ph.D. level MRI experts, Friebe and Gregor MD, surgeon and inventor, Andreas Melzer, MD Access to latest MRI devices Excellent connections in the MRI community Exciting, patented solutions

9 Core Business Offering our customers competitive advantage –Through proprietary solutions that can gain marketshare for them –FDA approval is pursued by the customer –Marketing and distribution of the final device is theirs We sell high margin components and develop annuities for our shareholders

10 Relationship With Boston Scientific Joint development agreement, originally entered into November, 2003 Recently moved to second and third phase, and has expanded to multiple products One of the companies referred to in recent 10Q Reached agreement on term sheet, working on final contract phase

11 SE coronal image of 3 aluminum wires (1/32”). Wire (3) is uncoated. 123 Biophan’s thin-film nanomagnetic particle coating technology provides a controllable, “magnetic” signal capable of creating an image of the coated device. #3 is uncoated. MRI Device Imaging

12 MR image artifacts occur when the magnetic field of the MRI scanner is “warped” or distorted by the presence of magnetizable material placed in the scanner (i.e. a medical device). Thin-film nanomagnetic particle coatings can “nullify” or neutralize the magnetization of the medical device and as a result, minimize or eliminate the image artifact. Multi-slice MR images of RF ablation probe showing distortion Oncology Imaging

13 Making Stents Imageable Seeing blockage of stents has required an invasive procedure Stents imageable under MRI would be competitively advantaged Biophan’s business is competitive advantage for our customers through technology innovation Nanoset has a coating solution AMRIS, now Biophan-Europe, has a “retrofit” solution Both solutions are PATENTED! Together we “cover the waterfront”

14 Implications Impact the $5+ billion stent market Help manufacturers make pacemakers, defibrillators, neurostimulators safe, and imageable – competitive advantage to our licensees Make guidewires, catheters, endoscopes, biopsy needles safe and image compatible Opens the field of interventional medicine under MRI (currently only X-Ray/Fluoroscopy)

15 Biothermal Battery Goal: To provide a long-lived electrical power system for implanted medical devices –Powered by body heat differential. Acquired 51% interest in TE-Bio, which holds an issued U.S. patent for the battery Batteries are a $500 million market, sell for $100 to $225 each in the pacemaker, defibrillator and drug pump markets Sold to same customers who need MRI safety

16 Agreement with NASA Announced on August 17 th a deal with NASA Ames Research Center for Nanotechnology to jointly develop the biothermal battery –NASA wants technology for their long duration manned MARS mission for biosensing and miniature therapeutic devices –Biophan gets commercial rights to jointly developed and NASA developed technology –Nanotechnology and materials science advances makes the biothermal battery possible

17 Substrate Polymer Coating Nanomagnetic layer Controlled Magnetic Field Drug bound to NMP carrier Controlled Magnetic Field A Controlled Magnetic Field B Particle type A Drug A Particle type B Drug B Surface Elution on Demand

18 Reloading Drug Eluting Coatings Substrate Polymer Coating Concentration Gradient Controlled Magnetic Field Drug Molecules Drug bound to NMP carrier Nanomagnetic layer

19 Guided Drug Delivery Solid tumor Apply magnetic field to concentrate particles Modulate field to release drug from particles Inject NMPs IV, NMP will circulate through the blood stream Other options for targeting: 1 - Direct injection into tumor site 2 - Coating NMP with antibodies to target tumor

20 Other Solution Offerings MRI Safe Drug Pump (non-magnetic) Nanomagnetic particles for contrast agents –Also used for MRI compatibility Reduce device heating Enable DRUG DELIVERY CAPABILITIES!

21 NanoView™ MRI Contrast Agents Nano-particulate technology has the potential to provide a new consumable product capable of significantly enhancing MR detection sensitivity (i.e. lowest detectable concentration) and specificity (i.e. the ability to reliably detect the desired substance).

22 PROTECTED, PROTECTED! Technologies covered by –127 U.S. Patents 37 ISSUED 90 pending or allowed 46 International Pending or Issued Owned by Biophan or licensed exclusively to Biophan for the medical market

23 Goals Close major deal – underway, at contract phase Close second deal – we have multiple prospects in the U.S. Europe, and Asia List on major exchange – requires $5 million capital, we meet all other qualifications, we plan to file as soon as capital in hand

24 Revenue Potential for MRI Safety and Visibility (by example, not a forecast) Customer Sales In Billion$ Year 3% (million$ yr) 5% (million$ yr) 13050 260100 390150 4120200 5150250 12360600

25 Sensitivities Deal Terms Improve with: –Proof of principle –Issued patents (the more the better) –Multiple prospects –Cash in the bank –Capability –Capacity

26 Other Markets Battery: $500 million Contrast Agents: $800 million Drug Pumps: $1 billion Drug Delivery: $40 billion Cautions: Penetration can take time FDA approval and/or CE Mark could take time Bright side is, once deal is underway, patents and annuity streams can last a long time

27 Biophan (OTC: BIPH) We don’t make medical devices; We make them safe, and imageable, for MRI And other competitive advantages for our customers Four of our six technologies are based on nanotechnology WWW.BIOPHAN.COM

28 Thank You! More good things will unfold in 2005! BIO med PHA rma N ano Technologies

Download ppt "Biophan Technologies, Inc. Company Overview Michael Weiner, CEO Pharma Finance 2005 Conference June 23, 2005."

Similar presentations

Ads by Google